Kalin Katherine Bach
SEC Form 4 insider trading activity
Kalin Katherine Bach has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Jan 9, 2026.
On the most recent filing, Kalin Katherine Bach is listed as Director at SELLAS Life Sciences Group, Inc. Inside the rolling window, Kalin Katherine Bach reported 1 open-market purchase totaling $101K in SLS and no open-market sales.
Companies traded
Other insiders at SLS
Insider Buying
$101K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Kalin Katherine Bach made?
Kalin Katherine Bach has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2025.
Which companies does Kalin Katherine Bach trade?
Kalin Katherine Bach has filed SEC Form 4 disclosures for 1 company, including SLS.
When was Kalin Katherine Bach's most recent SEC Form 4 filing?
Kalin Katherine Bach's most recent SEC Form 4 filing on Tracefour is dated Jan 9, 2026.
What is Kalin Katherine Bach's total buy and sell value in the current window?
Inside the rolling retention window, Kalin Katherine Bach bought $101K and sold $0 based on SEC Form 4 filings.
What was Kalin Katherine Bach's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 63,400 SLS shares on 2025-11-19, worth $101K, per SEC Form 4 filings.